Picture of Pacific Edge logo

PEB Pacific Edge Share Price

0.000.00%
nz flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m-3.25%
3m-19.76%
6m-27.19%
1yr-81.78%
Volume Change (%)
10d/3m-70.04%
Price vs... (%)
52w High-82.22%
50d MA-1.61%
200d MA-19.76%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-50.93%
Return on Equity-37.87%
Operating Margin-146.8%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Pacific Edge EPS forecast chart

Profile Summary

Pacific Edge Limited is a global cancer diagnostics company. The Company is engaged in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The Company operates through two segments: Commercial and Research. The Commercial segment is engaged in the sales, marketing, laboratory, and support operations to run the commercial businesses worldwide. The Research segment is engaged in the research and development of diagnostic and prognostic products for human cancer. The Company provides its suite of Cxbladder tests globally through its wholly owned laboratories in New Zealand and the United States. Its Cxbladder tests assist clinicians to safely de-intensify hematuria evaluation from low incidence populations; resolve diagnostic dilemmas, and monitor patients for the recurrence of urothelial carcinoma. It operates in New Zealand, Australia, Singapore, and the United States.

Directors

Last Annual
March 31st, 2023
Last Interim
September 30th, 2023
Incorporated
February 27th, 2001
Public Since
February 12th, 2003
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
nz flag iconNew Zealand Stock Exchange
Shares in Issue
810,717,000
Blurred out image of a map
Address
Centre for Innovation 87 St David St,, DUNEDIN, 9016
Web
https://www.pacificedgedx.com
Phone
+64 34795800
Contact
Kar Chun Fong
Auditors
PricewaterhouseCoopers Chartered Accountants

PEB Share Price Performance

Upcoming Events for PEB

Full Year 2024 Pacific Edge Ltd Earnings Release

Pacific Edge Ltd Annual Shareholders Meeting

Similar to PEB

Picture of Cannasouth logo

Cannasouth

nz flag iconNew Zealand Stock Exchange

FAQ